X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dersimelagon
Therapeutic Area: Immunology Product Name: MT-7117
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Details:
The Phase-2 study was a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of MT-7117 in subjects with diffuse cutaneous systemic sclerosis.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
